Erratum: Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network (PLoS ONE (2016) 8:1 (e53510) DOI: 10.1371/journal.pone.0053510);Chronic Morphine Treatment Attenuates Cell Growth of Human BT474 Breast Cancer Cells by Rearrangement of the ErbB Signalling Network

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Weingaertner, Inka Regine ^a   Koutnik, Sarah ^a   Ammer, Hermann ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; KAPPA OPIATE RECEPTOR; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MORPHINE; MU OPIATE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION;

EID: 84872143676     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153824     Document Type: Erratum

References (39)

1. Law PY, Wong YH, Loh HH, (2000) Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 40: 389-430.
2. Chen YL, Law PY, Loh HH, (2008) The other side of the opioid story: modulation of cell growth and survival signaling. Curr Med Chem 15: 772-778.
3. Tegeder I, Geisslinger G, (2004) Opioids As Modulators of Cell Death and Survival- Unraveling Mechanisms and Revealing New Indications. Pharmacological Reviews 56: 351-369.
4. Schulz R, Eisinger DA, Wehmeyer A, (2004) Opioid control of MAP kinase cascade. European Journal of Pharmacology 500: 487-497.
5. Heiss A, Ammer H, Eisinger DA, (2009) delta-Opioid receptor-stimulated Akt signaling in neuroblastoma x glioma (NG108-15) hybrid cells involves receptor tyrosine kinase-mediated PI3K activation. Exp Cell Res 315: 2115-2125.
6. Eisinger DA, Ammer H, (2011) Epidermal growth factor treatment switches delta-opioid receptor-stimulated extracellular signal-regulated kinases 1 and 2 signaling from an epidermal growth factor to an insulin-like growth factor-1 receptor-dependent mechanism. Mol Pharmacol 79: 326-335.
7. Nylund G, Pettersson A, Bengtsson C, Khorram-Manesh A, Nordgren S, (2008) et al. Functional expression of mu-opioid receptors in the human colon cancer cell line, Ht-29, and their localization in human colon. Dig Dis Sci 53: 461-466.
8. Kerros C, Cavey T, Sola B, Jauzac P, Allouche S, (2009) Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells. J Exp Clin Cancer Res 28: 77.
9. Warren CM, Landgraf R, (2006) Signaling through ERBB receptors: multiple layers of diversity and control. Cell Signal 18: 923-933.
10. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J, (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149.
11. Hermanto U, Zong CS, Wang L-H, (2001) ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Oncogene 20: 7551-7562.
12. Amin DN, Campbell MR, Moasser MM, (2010) The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol 21: 944-950.
13. Prigent SA, Gullick WJ, (1994) Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. Embo J 13: 2831-2841.
14. Lasfargues EY, Coutinho WG, Redfield ES, (1978) Isolation of two human tumor epithelial cell lines from solid breast carcinomas. J Natl Cancer Inst 61: 967-978.
15. Chen X, Yeung TK, Wang Z, (2000) Enhanced Drug Resistance in Cells Coexpressing ErbB2 with EGF Receptor or ErbB3. Biochemical and Biophysical Research Communications 277: 757-763.
16. Brockhoff G, Heiss P, Schlegel J, Hofstaedter F, Knuechel R, (2001) Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. Cytometry 44: 338-348.
17. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ, (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3: 269-280.
18. Eisinger DA, Ammer H, (2009) Down-regulation of c-Cbl by morphine accounts for persistent ERK1/2 signaling in delta-opioid receptor-expressing HEK293 cells. J Biol Chem 284: 34819-34828.
19. Eisinger DA, Ammer H, Schulz R, (2002) Chronic morphine treatment inhibits opioid receptor desensitization and internalization. J Neurosci 22: 10192-10200.
20. DeBlasi A, O' Reilly K, Motulsky HJ, (1989) Calculating receptor number from binding experiments using same compound as radioligand and competitor. Trends Pharmacol Sci 10: 227-229.
21. Toll L, (Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, (1998) et al. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178: 440-466.
22. Koltermann A, Liebl J, Furst R, Ammer H, Vollmar A, (2009) et al. Ginkgo biloba extract EGb 761 exerts anti-angiogenic effects via activation of tyrosine phosphatases. J Cell Mol Med 13: 2122-2130.
23. Johnson E, Seachrist DD, DeLeon-Rodriguez CM, Lozada KL, Miedler J, (2010) et al. HER2/ErbB2-induced breast cancer cell migration and invasion require p120 catenin activation of Rac1 and Cdc42. J Biol Chem 285: 29491-29501.
24. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sanchez V, (2011) et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 108: 5021-5026.
25. Belcheva MM, Tan Y, Heaton VM, (Clark AL, Coscia CJ, (2003) Mu opioid transactivation and down-regulation of the epidermal growth factor receptor in astrocytes: implications for mitogen-activated protein kinase signaling. Mol Pharmacol 64: 1391-1401.
26. Zagon IS, Rahn KA, McLaughlin PJ, (2007) Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells. Neuropeptides 41: 441-452.
27. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, (2008) et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68: 5878-5887.
28. Yarden Y, Sliwkowski MX, (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
29. Marmor MD, Skaria KB, Yarden Y, (2004) Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58: 903-913.
30. Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, (2008) et al. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS One 3: e2881.
31. Skolnik EY, Lee CH, Batzer A, Vicentini LM, Zhou M, (1993) et al. The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. Embo J 12: 1929-1936.
32. Castellano E, Downward J, (2011) RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer 2: 261-274.
33. Gijsen M, King P, Perera T, Parker PJ, Harris AL, (2010) et al. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol 8: e1000563.
34. Wennstrom S, Downward J, (1999) Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol Cell Biol 19: 4279-4288.
35. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, (2011) et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30: 2547-2557.
36. Afsharimani B, Cabot PJ, Parat MO, (2011) Morphine and tumor growth and metastasis. Cancer Metastasis Rev 30: 225-238.
37. Tegeder I, Grosch S, Schmidtko A, Haussler A, Schmidt H, (2003) et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res 63: 1846-1852.
38. Whistler JL, von Zastrow M, (1998) Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci U S A 95: 9914-9919.
39. Lerdrup M, Bruun S, Grandal MV, Roepstorff K, Kristensen MM, (2007) et al. Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus. Mol Biol Cell 18: 3656-3666.